Proton Therapy and Particle Therapy: Who Benefits the Most?

- Dr. Mushabbab Al Asiri — Director General of the Saudi National Cancer Centre and Chief Executive Supervisor of the Saudi Proton Therapy Center, he is also a Consultant Radiation and Clinical Oncologist at King Fahad Medical City and Prince Sultan Medical City with over three decades of experience in medicine, oncology, healthcare leadership, and cancer care, he has previously served as CEO of the Saudi Particle Therapy Center and held senior leadership positions at King Fahad Medical City and the Saudi Health Council
Oncology
Proton and particle therapy are advanced forms of external-beam radiation therapy that can improve dose distribution and reduce radiation exposure to surrounding healthy tissues. Their greatest potential benefit is observed when tumours are located near critical organs, when treatment requires high radiation doses, or when long-term toxicity reduction is particularly important. Proton therapy may be especially valuable for selected paediatric cancers, skull-base tumours, central nervous system malignancies, and other anatomically complex lesions. Heavier particles, such as carbon ions, may offer additional biological advantages for certain radioresistant tumours, although access and evidence remain more limited. Patient selection should consider tumour location, treatment intent, expected clinical benefit, availability, and cost. Multidisciplinary evaluation remains essential to determine whether particle therapy offers a meaningful advantage over contemporary photon-based radiation.